|Year : 2020 | Volume
| Issue : 2 | Page : 143-147
Effectiveness of the shorter MDR regimen in the management of tuberculosis: Shortfall in the outcome of disease a multidimensional approach and evaluation for a better alternative
Prasanta Kumar Das, Somtirtha B Ganguly
State TB Demonstration Cum Training Centre, Intermediate Reference Laboratory, Kolkata, West Bengal, India
|Date of Submission||11-Sep-2019|
|Date of Acceptance||07-Oct-2019|
|Date of Web Publication||17-Jun-2020|
Dr. Prasanta Kumar Das
State TB Demonstration Cum Training Centre, Intermediate Reference Laboratory, 2nd Floor, Dr. B. C. Roy Post Graduate Institute of Paediatric Sciences, 38, Badan Roy Lane, Kolkata 10, West Bengal
Source of Support: None, Conflict of Interest: None
Background: Shorter multidrug-resistant (MDR) regimen has proved to be very effective in some of the developing nations such as Bangladesh and several African countries. Various shortcomings in the execution of long-term MDR regimen have prompted for adapting the shorter regimen in India. The study explored the experience of the programmatic management of tuberculosis by a shorter regimen in West Bengal, India. Materials and Methods: Retrospective analysis of the data included the outcome analysis of the cured, lost to followup, treatment completed, treatment failure, treatment regimen changed and died. These attributes were analyzed. Results: Of the total 203 cases, cure rate accounted for 44.3%. Lost to follow-up was found to be 13.7%, in which alternative dispute resolution accounted for the major cause. A substantial amount of INH resistance is seen among the follow-up culture positive cases speculating the role of ethionamide in the regimen.
Keywords: Adverse drug reaction, line probe assay, lost to follow-up, multidrug-resistant shorter regimen
|How to cite this article:|
Das PK, Ganguly SB. Effectiveness of the shorter MDR regimen in the management of tuberculosis: Shortfall in the outcome of disease a multidimensional approach and evaluation for a better alternative. Biomed Biotechnol Res J 2020;4:143-7
|How to cite this URL:|
Das PK, Ganguly SB. Effectiveness of the shorter MDR regimen in the management of tuberculosis: Shortfall in the outcome of disease a multidimensional approach and evaluation for a better alternative. Biomed Biotechnol Res J [serial online] 2020 [cited 2022 Jan 22];4:143-7. Available from: https://www.bmbtrj.org/text.asp?2020/4/2/143/286840
| Introduction|| |
By definition, multidrug-resistant tuberculosis (MDR-TB) is a disease caused by Mycobacterium tuberculosis that is resistant to at least both rifampicin and isoniazid with or without resistance to other anti-TB drug.
The study was done from the routine samples received at Intermediate Reference Laboratory Kolkata under the Revised National Tuberculosis Control Program for the diagnosis and drug sensitivity of cases of TB, so the patient consent is implied.
The study was done under the ethical approval from the Central TB division for performing shorter MDR through State TB Cell, West Bengal, Vide No. HTB/Training-129/2012/460/1 (38) dated March 26, 2018. MDR-TB is a major public health challenge in developing nations. MDR-TB strains are resistant to at least Isoniazid (INH) and rifampin.
Rifampicin-resistant TB (RR-TB) is defined as TB caused by the M. tuberculosis complex strain resistant to rifampicin detected genotypically or phenotypically with or without resistance to other anti-TB drugs.
Due to poor management, drug-resistant TB MDR-TB/RR-TB has been emerging as a major problem.
The treatment of MDR-TB is very expensive, requires at least 2 years of treatment with potentially toxic drugs.,,,,,
The Global TB Report of 2016 estimated that 3.9% newly diagnosed and 21% of previously treated TB cases had MDR-TB.
Ethionamide (ETH) is one of the most important second-line anti-TB drugs; the chemical structure of ETH is similar to that of INH. Both inhibit the biosynthesis of mycolic acid.
Worldwide report on poor treatment outcomes was reported in most of the 2-year long conventional MDR treatment. The probable reasons include poor treatment adherence due to lengthy, expensive, and toxic regimens, leading to poor compliance.
This prompted a shorter regimen, an MDR TB regimen of 9–12 months instead of the conventional 2 years duration. The WHO has recommended extensive use of second-line line probe assay (LPA) tests to see the status of resistance for fluoroquinolones and second-line injectables before starting a shorter MDR regimen which has both these drugs.
Recently, WHO-recommended shorter regimen has proven successful in developing countries like Bangladesh.
India also started with the shorter MDR regime. The study explores the advantages and disadvantages of the regimen in the Indian demography. The study also explores the fallouts and deaths due to various reasons and the percentage contribution of the reasons for the attrition.
The molecular biology of INH resistance in M. tuberculosis has been thoroughly studied. INH is a prodrug which undergoes anin vivo transformation to its active form. Catalase-peroxidase (KatG) encoded by katG performs this function in M. tuberculosis, and mutations in katG, at codon 315, confer INH resistance. The activated INH has a primary target. It is an Nicotinamide adenine dinucleotide (NAD) + hydrogen (H)-dependent enoyl-acyl carrier protein reductase, designated InhA.
Mutations within the inhA structural gene,,, or within the inhA promoter,,,, are associated with both INH and ETH resistance., INH resistance occurs due to missense mutations within the inhA structural gene by reducing the NADH and protecting the enzyme from INH inactivation. The inhA promoter mutations upregulate the target expression, thereby rendering INH and ETH resistance., The structural similarity and shared molecular target of INH and ETH led to the conjecture that ETH, such as INH, undergoes activation.
| Materials and Methods|| |
This is a retrospective analysis of patients put of shorter MDR regimen as per the diagnostic algorithm of a programmatic management of drug-resistant TB under the Revised National Tuberculosis Control Program. The sample of these patients was initially tested at the peripheral unit by Cartridge based Nucleic Acid Amplfication Test. RR cases were selected for shorter MDR regimen as per the criteria by the WHO.
The patients selected for shorter MDR regimen are as follows:
- All pulmonary and extrapulmonary cases only pleural effusion and lymph nodes
- RR TB or MDR TB patient regardless of patient age or HIV status.
- All pregnant mothers
- Extrapulmonary cases other than pleural effusion and lymph nodes
- Previous exposure of more than 1 month to fluoroquinolones and second-line injectable group of drugs.
Smear examination of the patient selected for shorter MDR is done on a monthly basis in the intensive phase to guide decision-making to move to continuation phase. Smear examination is continued in the extended intensive phase only if the previous month smear is positive up to a maximum of 6 months. Follow-up cultures are done at the end of intensive phase, extended intensive phase, and at the end of treatment regime, and if found positive are subjected to first- and second-line LPA for the assessment of resistance, and if found resistance, modification regime is offered to the patient.
The outcomes of the treatment for all patients are declared only on the basis of follow-up culture.
During the course of treatment, samples of the patient are tested at specified intervals as follow-ups to assess the prognosis and outcome of the disease. Samples received at IRL Kolkata
| Statistical Analysis and Results|| |
This is a retrospective analysis of all the districts of West Bengal with a total of 203 cases which were subjected to shorter MDR regimen, of which 189 are pulmonary and 14 were extrapulmonary cases. Among these, 10 are reactive to HIV and are put on to antiretroviral therapy, 190 are nonreactive, and 3 are having unknown status. Of the 14 extrapulmonary cases, 6 are cases of tubercular lymphadenopathy (3 HIV reactive) and 8 are pleural effusion.
Among these, 35 patients are diabetic, of them 16 (45.7%) are having HbA1C >8% and are on oral hypoglycemic agents.
Of this, 27 (10 + 17) samples remain culture positive at the end of the intensive phase, of which 10 samples were declared treatment failure, and there were 17 cases in which treatment regimen were changed owing to several factors. Out of these cases 10 were having Isoniazid resistance either due to kat G or inhA. 4 cases among these group were sensitive to isoniazid by Line probe Assay. All these cases were however found to be resistant to rifampicin which were earlier confirmed by CBNAAT test prior to put on to shorter MDR regimen.
On further analysis it was found 6 follow up cultures (treatment ongoing samples) shows positivity in liquid culture. These cases were found sensitive to isoniazid. 4 of these cases were resistant to fluoroquinolones. 2 of these cases were found to be resistant to the second line injectables.
| Discussion|| |
Twentyseven (10 + 17) samples remain culture positive at the end of the intensive phase, of which 10 samples were declared treatment failure and 17 cases were from the group of treatment regimen changed 8.37%. The outcomes of the patient were put on the shorter MDR regimen, Bangladesh, Uzbekistan, Cameroon, Nigeria, and other different countries of sub-Sahara African belt. Success rate does not match with our selection of cases in the specified duration which does not reflect the success rate, as 13.7% [Table 1] of the cases were lost to follow-up in the duration study as majority of the cases turned to lost to follow-up had probably migrated to a different state or to different nation of close proximity.
|Table 1: Outcome of shorter multidrug-resistant regimen in the study (n=203)|
Click here to view
Adverse drug reactions added significantly to the lost to follow-up cases which was about 13.7% [Table 1]. Headache along with vomiting accounted for 21.0% [Table 2]. After headache and vomiting, drug fever and skin rashes accounted for 18.4% [Table 2]. Cure rate accounted for 44.3% [Table 1].
|Table 2: Adverse reaction noted in different case with shorter multidrug-resistant regimen (n=38)|
Click here to view
INH inhibits the process of mycolic acid synthesis. Mutations in the katG gene or the inhA regulatory regions leads to INH resistance.
INH is rendered ineffective for the treatment of M. tuberculosis if encountered mutation. The inhA regulatory region which encodes the primary target of active INH is nicotinamide adenine dinucleotide-dependent enoyl-acyl carrier protein reductase.,, ETH and prothionamide. inhA mutations cause low-level resistance to the molecule meaning that higher doses may be effective.,
As ETH is a structural analog of INH, cross-resistance occurs between INH and ETH;,, thus, ETH and low-level INH show cross-resistance. A clinical trial has shown adding high-dose INH systematically to a standard MDR-TB regimen which has been effective. ETH is judiciously used in case of MDR- or XDR-TB strains with katG mutations.,
Of those who had failed to get cured on shorter MDR regimes were further subjected to first-line LPA based on sputum microscopy, and those which were smear negative in between the course of treatment were put on liquid culture and subsequently subjected to first-line LPA.
| Conclusion|| |
Initiating a MDR regimen requires a modified selection criteria. The criteria should exclude isoniazid resistant cases owing to its cross resistance wth Ethionamide. As ETH is one of the challenging drugs selected in the shorter MDR regime, a simultaneous detection of RR status by CBNAAT at periphery and putting these samples for first-line as well as second-line LPA needs to be implemented prior to the selection of shorter MDR regime.
Twelve percentage of cases which were culture positive after the initiation of treatment with shorter MDR regime found to be resistant to fluoroquinolones groups or second-line injectable class resistance or both and lead to modification of treatment. Furthermore to note that the patient receiving the regimen where compelled to change the injectable kanamycin due to intolerability in the initial course of therapy have varied symptoms.
Studies were conducted for determining newer drug targets. Even extensive studies are required for detecting the wellknown drug targets (new drugs for TB) such as InhA, RpoB, FabC, FabD, KasA, Ndh, Glf, EfpA, EmbB, ES31, Cyp125, and InhA. FASII enoyl-ACP reductase (InhA) is the only well-validated target of the TB drug INH and has been a target of the rational drug design.
Generally, the cost per diagnosis of using GeneXpert has proved to be very cost-effective among the elderly, but the study included project samples which were facilitated by free drugs and diagnostic services; the cost-effectiveness for the patients was not very significant.
It is evident that there is a substantial risk for developing even more resistant forms of TB due to the usage of suboptimal drugs.
Earlier, it was observed that after the initiation of treatment starting treatment 48 had a successful outcome, 6 (12%) treatment failed, 19 (38%) died, and one (2%) interrupted treatment.
In a study, MDR MTB was noted in 66/113 patients, including 20 CAT I failure, 19 CAT II failure, and 27 CAT II relapse cases. Resistance to isoniazid (H) was seen most frequently in 74% of the patients, followed by resistance to pyrazinamide (Z).
Based on our study, we had concluded that shorter MDR regimen is probably not the concrete solution for the patient having rifampicin-resistance status due to multifactorial events and nonadherence to the treatment on the patient part. Furthermore, studies are needed to evaluate the impact of shorter MDR regimen in different geographical region globally.
To establish this, an injectable-free regime needs to be formulated for avoiding the noncompliance and nonadherent to the treatment and minimization of adverse reactions and also lost to follow-up.
Twelve percentage of cases which were culture positive after initiation of treatment with shorter MDR regime found to be resistant to fluoroquinolones groups or second-line injectable class resistance or both and lead to modification of treatment
More similar studies should be explored in different geographical domains for similar cases with shorter MDR regimes to evaluate further the acceptability, tolerability, and compliance at the patient end to keep it as a definite regime in the management of drug resistance TB.
There are various studies in the developing and underdeveloped countries like Bangladesh and African countries where the outcome of a shorter MDR regimen is appreciably good in a range of 65%–85%. However, in our study, it turned to be 44.3% [Table 1], which is even less than the conventional regimen. Most studies need to be done in different provinces of our country with similar various dimensions related to shorter MDR regimen to establish the impact and outcome of regimen.
With the outcome of our study in the field of management of MDR TB, shorter MDR regimen is not appreciably good with multidimensional problems related to low cure rate, intolerability of the drugs included, and cross-resistance of isoniazid with ETH, an insight to be kept for a patient friendly regimen, preferably injectable free and good acceptability with high cure rate. This may be a strong pillar for the management of drug-resistant TB.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
World Health Organization. Anti-Tuberculosis Drug Resistance in the World. Report No. 2. Prevalence and Trends. Geneva, Switzerland: World Health Organization; 2000.
Crofton JP, Chaulet D, Maher J, Grosset W, Harris H, Norman M, et al
. Watt. Guidelines for the Management of Multidrug Resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 1997.
World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug Resistant Tuberculosis. Geneva: World Health Organization; 2014.
Central TB Division. Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India. New Delhi: Directorate of General Health Services, Ministry of Health and Family Welfare, Government of India; 2012.
Prasad R, Srivastava DK. Multidrug and extensively drug resistant TB (M/XDR TB) management: Current issues. Clin Epidemiol Glob Health 2013;1:124-8.
Prasad R. Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies. Lung India 2012;29:154-9. [Full text]
Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
. Nature 1992;358:591-3.
Blanchard JS. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis
. Annu Rev Biochem 1996;65:215-39.
Larsen MH, Vilchèze C, Kremer L, Besra GS, Parsons L, Salfinger M, et al.
Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis
, M. bovis
BCG and M. tuberculosis
. Mol Microbiol 2002;46:453-66.
Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al.
InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis
. Science 1994;263:227-30.
Basso LA, Zheng R, Musser JM, Jacobs WR Jr., Blanchard JS. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis
: Enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis 1998;178:769-75.
Kapur V, Li LL, Hamrick MR, Plikaytis BB, Shinnick TM, Telenti A, et al.
species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis
by automated DNA sequencing. Arch Pathol Lab Med 1995;119:131-8.
Ristow M, Möhlig M, Rifai M, Schatz H, Feldmann K, Pfeiffer A. New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis
strains. Lancet 1995;346:502-3.
Lee H, Cho SN, Bang HE, Lee JH, Bai GH, Kim SJ, et al.
Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis
isolates from Korea. Int J Tuberc Lung Dis 2000;4:441-7.
Morris S, Bai GH, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis
. J Infect Dis 1995;171:954-60.
Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and – Susceptible strains of Mycobacterium tuberculosis
by automated DNA sequencing: Restricted array of mutations associated with drug resistance. J Infect Dis 1996;173:196-202.
Rouse DA, Li Z, Bai GH, Morris SL. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis
. Antimicrob Agents Chemother 1995;39:2472-7.
Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr., Sacchettini JC. Modification of the NADH of the isoniazid target (inhA) from Mycobacterium tuberculosis
. Science 1998;279:98-102.
Baulard AR, Betts JC, Engohang-Ndong J, Quan S, McAdam RA, Brennan PJ, et al.
Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem 2000;275:28326-31.
Takayama K, Wang L, David HL. Effect of isoniazid on thein vivo
mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis
. Antimicrob Agents Chemother 1972;2:29-35.
Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis
: A systematic review. PLoS One 2015;10:e0119628.
Scardigli A, Caminero JA. Management of drug-resistant tuberculosis. Curr Respir Care Rep 2013;2:208-17.
Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis
. Int J Tuberc Lung Dis 2009;13:1320-30.
Müller B, Streicher EM, Hoek KG, Tait M, Trollip A, Bosman ME, et al.
InhA promoter mutations: A gateway to extensively drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis 2011;15:344-51.
Moulding TS. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am Rev Respir Dis 1981;123:262-4.
Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139-45.
Jena L, Harinath BC. Anti-tuberculosis therapy: Urgency for new drugs and integrative approach. Bio Biotech Res J 2018;2:16-9.
Sookaromdee P, Wiwanitkit V. Cost-effectiveness analysis of classical sputum examination versus molecular diagnosis by genexpe. Bio Biotech Res J 2019;3:210-1.
Hoffner SE. The role of drug susceptibility testing in M/XDR-TB. Too little and too late – Are we doing the right things? Int J Mycobacteriol
Milanov V, Falzon D, Zamfirova M, Varleva T, Bachiyska E, Koleva A, et al.
Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009-2010. Int J Mycobacteriol
Ghafoor A, Mehraj J, Afridi ND, Rafiq Y, Wendl-Richter HU, Hasan R, et al.
Multidrug resistant Mycobacterium tuberculosis
amongst category I and II failures and category II relapse patients from Pakistan. Int J Mycobacteriol 2012;1:118-23. [Full text]
[Table 1], [Table 2]